ICR-CTSU clinical trials
Enrolling participants
ATARI
ATARI investigates whether a new type of drug could help treat people with certain types of gynaecological cancers that have come back after treatment.
AURORA
Aiming to understand the molecular aberrations in metastatic breast cancer.
HER2-RADiCAL
HER2-RADiCAL is investigating whether some people with HER2 positive breast cancer can safely receive less treatment after surgery.
InPACT
International penile advanced cancer trial - an International Rare Cancers Initiative study.
KORTUC
Randomised phase II trial testing efficacy of intra-tumoural hydrogen peroxide as a radiation sensitiser in patients with locally advanced/recurrent breast cancer
In follow-up
ABC
UK Co-ordinating Committee on Cancer Research randomised trial of adjuvant endocrine therapy and chemotherapy in women with early breast cancer.
ART DECO
Randomised multicentre accelerated radiotherapy study of dose escalated intensity modulated radiotherapy versus standard dose intensity modulated radiotherapy in patients receiving treatment for locally advanced laryngeal and hypopharyngeal cancers.
AZURE
Does adjuvant zoledronic acid reduce recurrence in patients with high risk localised breast cancer?
BASO DCIS II
Randomised trial testing observation (no radiotherapy) against radiotherapy in women with low risk completely excised ER+ ductal carcinoma in situ of the breast on adjuvant endocrine therapy.
BC2001
Randomised phase II study of radiotherapy with and without synchronous chemotherapy in muscle invasive bladder cancer.
BIG2-06 ALTTO
A randomised, multicentre, open label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2+/ErbB2+ primary breast cancer.
BIG4-11 APHINITY
A randomised, multicentre, double blind, placebo controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2+ primary breast cancer.
CASPS
Phase II trial of cediranib in the treatment of patients with alveolar soft part sarcoma.
CHHiP
Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer.
CORAL
A phase II study of abiraterone in patients with recurrent ovarian, fallopian, or primary peritoneal cancer.
CORE
Conventional care versus Radioablation (stereotactic body radiotherapy) for extracranial oligometastases.
CTC-STOP
Utilising Circulating Tumour Cell (CTC) counts to optimize systemic therapy of metastatic prostate cancer.
c-TRAK TN
A randomised trial utilising ctDNA mutation tracking to detect minimal residual disease and trigger intervention in patients with moderate and high risk early stage triple negative breast cancer.
DARS
A phase III randomised multicentre study of dysphagia optimised intensity modulated radiotherapy (Do-IMRT) versus standard intensity modulated radiotherapy (S-IMRT) in head and neck cancer.
FAST
Prospective randomised clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control.
FAST-Forward
FAST-Forward is investigating whether a shorter course of radiotherapy treatment for people with breast cancer is as safe and effective as the standard longer course.
HALT
HALT investigates a treatment option for advanced non-small cell lung cancer.
HERA
A randomised three arm multicentre comparison of 1 year and 2 years of trastuzumab (Herceptin®) versus no trastuzumab in women with HER2+ primary breast cancer who have completed adjuvant chemotherapy.
HOT
Randomised phase II trial of hyperbaric oxygen therapy for patients with chronic arm lymphoedema after radiotherapy for early breast cancer.
HYBRID
A multicentre, randomised phase II study of hypofractionated bladder radiotherapy with or without image guided adaptive planning.
IMPORT HIGH
Randomised trial testing dose escalated intensity modulated radiotherapy for women treated by breast conservation surgery and appropriate systemic therapy for early breast cancer.
IMPORT LOW
Randomised trial testing intensity modulated and partial organ radiotherapy following breast conservation surgery for early breast cancer.
INOVATE
A multicentre prospective biological sample collection and analysis study, which aims to validate circulating Human Papilloma Virus (HPV) DNA as a marker of residual disease in patients with HPV positive oropharyngeal cancer (OPC).
LopeRA
Randomised controlled trial of laparoscopic, open and robot assisted prostatectomy as treatment for organ confined prostate cancer.
Closed
111 trial
Single group trial evaluating one cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy in high risk, stage 1 non seminomatous germ cell tumours of the testis.
ACTION
Phase III randomised controlled trial testing the benefit and tolerability of adjuvant chemotherapy in patients aged 70 and over with early stage ER negative or ER weakly positive breast cancer.
A-PREDICT
Phase II study of axitinib in patients with metastatic renal cell cancer unsuitable for nephrectomy.
BOXIT
Randomised phase III placebo controlled trial evaluating the addition of celecoxib to standard treatment of transitional cell carcinoma of the bladder.
CALIBER
Phase II randomised feasibility study of chemoresection and surgical management in low risk non muscle invasive bladder cancer.
COSTAR
A multicentre randomised study of cochlear sparing intensity modulated radiotherapy versus conventional radiotherapy in patients with parotid tumours.
DEVA
A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer.
EPHOS-B
Effect of perioperative anti-HER2 therapy on early breast cancer study – biological phase.
FEC trial
Two randomised trials comparing chemotherapy regimens CMF and FEC in node positive and node negative primary breast cancer.
ICCG FEMTX Trial
Adjuvant phase III randomised study of high dose methotrexate and 5-Fluorouracil combined with epirubicin (FEMTX) versus control in patients with resected gastric cancer.
ICCG High Dose Study
Randomised trial of high dose therapy using cyclophosphamide, thiotepa and carboplatin in primary breast cancer patients with 4 or more histologically involved positive nodes.
ICCG HMFEC Trial
FE 50 C versus FE 75 C with or without sequential hormone therapy in women with node positive premenopausal breast cancer.
ICCG IES
The Intergroup Exemestane Study (IES) is a randomised double-blind trial in postmenopausal women with primary breast cancer who have received adjuvant tamoxifen for 2-3 years, comparing subsequent adjuvant exemestane treatment with further tamoxifen to complete a total of 5 years endocrine therapy.
ICCG Neocent
Neoadjuvant study of chemotherapy versus endocrine therapy in postmenopausal patients with primary breast cancer
Intercontinental
Intercontinental is an international phase III randomised trial comparing intermittent versus continuous androgen suppression for patients with prostate-specific-antigen progression in the clinical absence of distant metastases following radiotherapy for prostate cancer.
MA32
A phase III randomised trial of metformin versus placebo on recurrence and survival in early stage breast cancer
MAPLE
Double-blind short term pre-surgical study to assess the molecular antiproliferative predictors of lapatinib’s effects in breast cancer.
MARS
Mesothelioma and radical surgery trial.
MSG/BAPS
Randomised trial of width of excision of thick cutaneous malignant melanoma.
NICAM
Phase II trial of nilotinib in the treatment of patients with c-KIT mutated advanced acral and mucosal melanoma.
PACE
International randomised study of laparoscopic prostatectomy vs stereotactic body radiotherapy (SBRT) and conventional radiotherapy vs SBRT for early stage organ-confined prostate cancer.